Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia. |
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
ufc6ddZmqB16zNqb
